Charles Zhu
Stock Analyst at Guggenheim
(2.40)
# 2,507
Out of 5,152 analysts
19
Total ratings
47.06%
Success rate
15.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Maintains: Buy | $10 → $12 | $16.83 | -28.70% | 4 | Oct 24, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $22 | $11.33 | +94.17% | 1 | Jun 18, 2025 | |
| MGNX MacroGenics | Upgrades: Buy | $12 | $2.14 | +460.75% | 4 | Nov 7, 2023 | |
| NUVL Nuvalent | Initiates: Buy | $56 | $100.13 | -44.07% | 1 | Jul 24, 2023 | |
| TARA Protara Therapeutics | Assumes: Buy | $22 | $5.82 | +278.01% | 1 | Jul 10, 2023 | |
| COGT Cogent Biosciences | Reiterates: Buy | $26 | $37.46 | -30.59% | 3 | Jun 13, 2023 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $33.03 | -3.12% | 3 | Mar 8, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $14 | $24.80 | -43.55% | 2 | May 5, 2022 |
Tango Therapeutics
Oct 24, 2025
Maintains: Buy
Price Target: $10 → $12
Current: $16.83
Upside: -28.70%
Crescent Biopharma
Jun 18, 2025
Initiates: Outperform
Price Target: $22
Current: $11.33
Upside: +94.17%
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $2.14
Upside: +460.75%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $100.13
Upside: -44.07%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $5.82
Upside: +278.01%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $37.46
Upside: -30.59%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $33.03
Upside: -3.12%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $24.80
Upside: -43.55%